Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Carboplatin in BRCA-mutated mCRPC
NCT02598895Phase 2Completed
- Sponsor
- University of Washington
- Start
- Jan 2016
- Primary completion
- Sep 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Washington. Started Jan 2016; status: completed.
02
Drugs
carboplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02598895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598895.